ResMed (NYSE: RMD) reported Q4 EPS of $0.77, $0.02 better than the analyst estimate of $0.75. Revenue for the quarter came in at $556.7 million versus the consensus estimate of $555.73 million.

For earnings history and earnings-related data on ResMed (RMD) click here.